Month: March 2025

MUNICH, March 25, 2025 (GLOBE NEWSWIRE) — From April 7th to 13th, bauma 2025 is to take place in Munich, Germany. In this top industrial fair, global machinery firms will show leading technologies and innovations in the Trade Fair Center Messe München. As a globally leading equipment manufacturer, Zoomlion has exhibited at bauma for 8 years in a row. What will be its blockbusters in 2025? In the fair, Zoomlion will focus on “Greener Development, Brighter Future” and exhibit near 70 premium products for concrete machinery, mobile crane, construction hoisting machinery, earth-moving machinery, MEWPs, and industrial vehicles. Its Italian subsidiary CIFA and German subsidiary M-TEC will jointly exhibit their best-selling products. Based on AI, digital twins, and IoT, Zoomlion develops complete sets of mining machinery equipment solutions...

Technip Energies (PARIS:TE), a global technology & engineering powerhouse leading in energy and decarbonization infrastructure, today announces the publication of the convening notice for its annual general meeting, which will be held on May 6, 2025, at 2:00 p.m. CEST in Schiphol, The Netherlands. The convening notice, agenda and explanatory notes, as well as other relevant meeting documents are available at: https://investors.technipenergies.com/news-events/agm Technip Energies’ 2024 Annual Report is available at: https://investors.technipenergies.com/financial-information/results-center About Technip Energies Technip Energies is a global technology and engineering powerhouse. With leadership positions in LNG, hydrogen, ethylene, sustainable chemistry, and CO2 management, we are contributing to the development of critical markets...

Seasoned Agriculture and Biotech Executive With a Passion to Feed the World Sustainably Ghent, BELGIUM, March 25, 2025 (GLOBE NEWSWIRE) — Press release Biotalys (Euronext: BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for sustainable crop protection, is pleased to announce the proposal to appoint Toni Bucci as independent director to its Board of Directors. Ms Bucci’s appointment will become effective immediately upon election at the upcoming Biotalys shareholders’ meeting on 22 April 2025. She will succeed Markus Heldt, who will retire from the Board. Simon Moroney, Chairman of the Board at Biotalys, commented: “We are delighted to welcome Toni Bucci to our Board of Directors. Her extensive experience in agriculture and strategic leadership will be most welcome as we continue...

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosisLong-term disability and safety data from ALITHIOS open-label extension study on continuous treatment with Kesimpta vs. later switch from teriflunomide in relapsing multiple sclerosis (RMS) patients to be presentedAdditional presentations highlight the Novartis neuroscience pipeline, including remibrutinib for RMS and iptacopan for generalized myasthenia gravisBasel, March 25, 2025 – Novartis will present data from studies across its neuroscience portfolio, including seven-year disability outcomes and safety data from the ALITHIOS open-label extension trial of Kesimpta® (ofatumumab) in people with relapsing multiple sclerosis (RMS), at the American Academy of Neurology (AAN) 2025...

Ladies and Gentlemen Please find enclosed the invitation to the Ascom Annual General Meeting 2025. This will take place on Wednesday, April 16, 2025, at 2 p.m.The venue is the Theater Casino Zug, Artherstrasse 2-4, 6300 Zug. Further details on the meeting and the agenda can be found in the official invitation enclosed. Yours sincerelyAscom Holding AGAttachmentAscom_Invitation_AGM_2025

HIGHLIGHTS:Montage to obtain up to 19.9% ownership stake in African Gold (ASX:A1G), through the issuance of up to 2.19 million common shares for deemed aggregate consideration of up to circa C$6.3 million African Gold to appoint Silvia Bottero, EVP Exploration of Montage, as Non-Executive Director and Martino De Ciccio, CEO of Montage, as Strategic Advisor to the Board of Directors African Gold owns several exploration properties in Côte d’Ivoire, including its flagship Didievi project which hosts an Inferred Resource of 4.93Mt at 2.9 g/t Au containing 452,000oz of gold, as published by African Gold Montage appointed operator of the Didievi project to take advantage of its presence and expertise in Côte d’Ivoire African Gold is currently undertaking a 10,000-meter drill programme at its Didievi project which continues to return high-grade...

HOUSTON, March 24, 2025 (GLOBE NEWSWIRE) — Prairie Operating Co. (“Prairie,” the “Company,” “we,” or “our”) (Nasdaq: PROP) announced today the pricing of an underwritten public offering of $38.5 million (the “Common Stock Offering”) of shares of its common stock, par value $0.01 (“Common Stock”) at a price to the public of $4.50 per share. The underwriters have a 30-day option to purchase up to an aggregate value of $5.8 million of additional shares of Common Stock. Net proceeds to Prairie from the sale of the $38.5 million of shares of its common stock, after the underwriting discount and commissions and estimated offering expenses, will be approximately $35.4 million (or $40.8 million, if the underwriters exercise their option in full). The Company intends to use the net proceeds from the Common Stock Offering, together with...

Tokyo, Japan and Cambridge, UK, 25 March 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Tempero Bio, Inc. has initiated a Phase 2 trial of TMP-301, a potent, selective and orally available mGluR5 negative allosteric modulator (NAM), for the treatment of alcohol use disorder (Clinical Trial ID: NCT06648655). The full announcement from Tempero Bio can be found by clicking here, in which Tempero Bio also announces the close of a $70 million financing, the proceeds of which will be used to advance TMP-301 through the Phase 2 trial for alcohol use disorder and a second Phase 2 trial in cocaine use disorder planned to start over the next year. The funds will also be used by Tempero Bio to conduct Phase 3-enabling activities for TMP-301 and preclinical studies for additional indications and formulations. The...